Convergence Pharmaceuticals (United Kingdom) a clinical-stage small molecule company focused on the treatment of neuropathic and chronic pain, closed a $35.4M Series A financing. Participants include New Leaf Venture Partners, Apposite Capital and SV Life Sciences.